We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Any diamonds in the diagnostic coal?
- Authors
Jacobs, Tom
- Abstract
The article reports that companies are not reaping the kind of returns they had expected when they invested in diagnostics businesses. Today, over six years after Celera Genomics's initial public offering and coming up on 13 years for Incyte Genomics Corp.'s, both are cash starved. Myriad Genetics is far worse off financially, without either accounting profits or free cash flow, and its investors there have earned a mediocre 7.1% CAGR since the October 6, 1995 IPO close.
- Subjects
DIAGNOSIS; CORPORATE finance; GENETICS; INCYTE Corp.; CELERA Genomics Group (Company); INVESTORS
- Publication
Nature Biotechnology, 2006, Vol 24, Issue 8, p930
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0806-930